Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Down 59.3% in April

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a large decrease in short interest in April. As of April 15th, there was short interest totalling 27,400 shares, a decrease of 59.3% from the March 31st total of 67,400 shares. Approximately 3.6% of the shares of the company are sold short. Based on an average daily trading volume, of 1,380,000 shares, the days-to-cover ratio is currently 0.0 days.

Bio-Path Stock Performance

Shares of Bio-Path stock traded up $0.05 on Friday, hitting $2.68. The stock had a trading volume of 117,216 shares, compared to its average volume of 4,416,653. The stock has a 50 day moving average of $4.77 and a 200 day moving average of $8.36. Bio-Path has a twelve month low of $2.35 and a twelve month high of $44.80. The firm has a market capitalization of $1.82 million, a P/E ratio of -0.07 and a beta of 0.35.

Bio-Path (NASDAQ:BPTH) last issued its quarterly earnings data on Friday, March 8th. The company reported ($5.40) earnings per share for the quarter, hitting the consensus estimate of ($5.40). During the same quarter in the prior year, the firm posted ($10.60) earnings per share. Equities analysts expect that Bio-Path will post -18.71 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on BPTH shares. Roth Mkm reiterated a “buy” rating and issued a $40.00 price objective on shares of Bio-Path in a research note on Thursday, April 18th. StockNews.com assumed coverage on Bio-Path in a research report on Wednesday. They set a “sell” rating on the stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.